Abstract IA003: Prevention of taxane-induced peripheral neuropathy

Abstract Chemotherapy-induced peripheral neuropathy (CIPN) is a common and severe dose-limiting toxicity of several widely used neurotoxic chemotherapy agents, including paclitaxel and docetaxel. CIPN is extremely prevalent and has a profound impact on quality of life, often limiting daily functioning and motor activities, and can persist for years after treatment. At present, dose modification remains the most successful approach to prevent worsening CIPN; however, there is potential for lower chemotherapy efficacy, which could result in poorer survival. No neuroprotective agents have been proven to effectively prevent CIPN. Cryotherapy, compression therapy, and cryocompression therapy are promising non-pharmacological interventions, but are not yet recommended for use in clinical practice as rigorous, large randomized trials are needed to prove efficacy. Compared to cryotherapy with frozen gloves, preliminary evidence suggests that continuous-flow cryotherapy (with or without cyclic compression) and continuous compression therapy may be safer, more tolerable, and potentially easier to implement on a large scale. Cryocompression therapy may also be more effective than cryotherapy alone. Thus, it is important to rigorously evaluate these modalities in a randomized controlled trial. This talk will review the preliminary evidence supporting the role of cryotherapy, compression therapy, and cryocompression therapy in CIPN prevention. It will discuss the ongoing ICE COMPRESS clinical trial (NCT05642611), a large phase III randomized controlled trial evaluating the efficacy of cryocompression versus continuous compression versus low cyclic compression (control) for the prevention of taxane-induced peripheral neuropathy. Citation Format: Kathryn Pennington. Prevention of taxane-induced peripheral neuropathy [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research; 2025 Sep 19-21; Denver, CO. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl):Abstract nr IA003.